A Study of HS-20094 in Patients With T2DM

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 275 participants.

Also called NCT06901648

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 275 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06901648
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06901648. Randomized; double masking; primary purpose treatment. Start 2024-02-06 (actual); primary completion 2025-03-07 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of HS-20094 in Patients With T2DM
Intervention (Drug)
HS-20094
Intervention (Drug)
Dulaglutide
Intervention (Drug)
Palcebo
Lead sponsor
Jiangsu Hansoh Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct06901648
Content hash
313eb333aecb0c03dfa72eab6e313565932413096b02b2939022b67e818d578b